2012 BIO International Convention: Academic and Tech Transfer Community

Patently BIOtech

Universities have historically been on the front lines of translating innovative research into novel medicines and technologies useful to patients.  With that in mind, the 2012 BIO International Convention will look to highlight the role of academia in the advancement of the biotechnology field through the BIO Academic Park and the Translational Research Forum. Hosted by the Biotechnology Industry Organization (BIO), this year’s global event for biotechnology will take place June 18-21, 2012 at the Boston Convention and Exhibition Center in Boston, MA.

“The BIO Academic Park will give Convention attendees the opportunity to connect and start conversations that could lead to partnerships, and most importantly, establish a tighter link between academic, industry representatives and investors,” said Dr. Abigail Barrow, Founding Director of the Massachusetts Technology Transfer Center and Program Co-Chair of the 2012 BIO International Convention.

To hear more from Dr. Abigail Barrow and her thoughts on the importance of academic-industry partnerships for driving innovation and the 2012 BIO International Convention, check out this podcast.

BIO along with AstraZeneca, MedImmune and the Massachusetts Association of Technology Transfer Offices (MATTO) are sponsoring and organizing the inaugural BIO Academic Park at this year’s Convention.  The Park is the first ever dedicated zone to academics and will serve as a pavilion for academic and industry partnering meetings as well as provide a venue for highlighting the involvement of academia in the Convention and the industry as a whole. BIO attendees will also have the opportunity to meet with Tech Transfer office representatives in the BIO Academic Park.

A special program for collaborating with the academic community and industry, The Translational Research Forum: From Bench to Bedside in a Bioeconomy – Government, Industry and University Models to Catalyze Economic Growth and Patient Access, will explore how universities and their funding partners can move early stage research forward in order to make them attractive to developers. The Forum will provide specific examples of innovative university models which increase patient access to innovative products and spur economic growth. Sponsored by Millennium: The Takeda Oncology Company;  Investissement Québec and the University of Virginia, the Forum will take place Monday, June 18th, 1:30 – 6:30 p.m. in Room 205 BC.

Translational Research Forum agenda highlights include:

  • Welcome Remarks: W. Mark Crowell, Executive Director, UVA Innovation and Associate Vice President, University of Virginia
  • Opening Remarks: Karen Ferrante, Chief Medical Officer, Millennium: The Takeda Oncology Company
  • Keynote Address: The Role of Universities in Translational Medicine: Robert A. Brown, PhD, President, Boston University
  • Panel Discussions: Strategies for Transitioning Basic Science into the Translational Research Arena

Panel – Basic Discovery Stage

Moderator: Stephen F. Flaim, Ph.D., FACC, FAHA, Special Advisor (contractor), Office of Translational Alliances & Coordination, Division of Extramural Research Activities, National Heart, Lung and Blood Institutes, National Institutes of Health (NIH)

Panelists: Jodi Black, PhD, Deputy Director, Division of Extramural Research Activities National Heart Lung and Blood Institute, National Institutes of Health (NIH) and Curtis Keith, PhD, Chief Scientific Officer, Biomedical Accelerator Fund, Office of Technology Development, Harvard University 

Panel – Strategies for Proof of Concept and Translational Research within Universities

Moderator: Todd Sherer, PhD, Director, Technology Transfer, Emory University, and President, Association of University Technology Managers (AUTM)

Panelists: Paul Corson, Deputy Director, Office of Innovation and Entrepreneurship, US Department of Commerce and David Day, Assistant Vice President and Director, Office of Technology Licensing and Sid Martin Biotechnology Incubator, University of Florida, and Bahija Jallal, PhD, Executive Vice President, Research & Development, MedImmune

Panel – Corporate Strategies for Accessing External Early-Stage Innovation

Moderator: Robert Zivin, PhD, Senior Director, Corporate Office of Science and Technology, Johnson & Johnson

Panelists: Mark Bodmer, PhD, Vice President and Area Therapy Head Immunology, UCB S.A. and Ronald C. Newbold, PhD, Vice President, Strategic Research Partnerships, External R & D Innovation, Worldwide Research & Development, Pfizer Inc.

  • Closing Remarks and Networking Reception

To learn more about the Academic Zone, Translational Research Forum and the various universities and academic attendees, please visit http://convention.bio.org/academic.

Patently BIOtech  |  Email This Post  |  Printer Friendly
Tags: , , ,

Leave a Reply

Your email address will not be published. Required fields are marked *

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>